HOPE Act Final Regulatory Impact Analysis

The Health Resources and Services Administration (HRSA) has issued the final Regulatory Impact Analysis (RIA) for the HOPE Act. This analysis, identified by docket number HRSA-2024-0001-0058, provides a comprehensive review of the potential economic effects, including costs and benefits, associated with the HOPE Act's provisions. It serves as a final assessment prior to or concurrent with the full implementation of the Act.

While this RIA is a final document, it does not impose new direct obligations on regulated entities. However, it informs stakeholders, including drug manufacturers, pharmaceutical companies, and healthcare providers, about the economic landscape shaped by the HOPE Act. Compliance officers should review the analysis to understand the agency's finalized assessment of the Act's impact, which may inform strategic planning and resource allocation related to the Act's requirements.